Navigation Links
Benda Pharmaceutical Reports Third Quarter 2008 Financial Results
Date:11/18/2008

esearch and development expenses (249,357) (310,084) (79,576) (212,965) Total operating expenses (7,934,157) (13,030,427) (1,811,924) (2,050,956) Operating income / (loss) (684,494) (5,340,525) 608,970 1,738,208 Interest income / (expenses) (3,339,457) (2,207,878) (998,877) (1,141,472) Other income (expenses) 10,140 113,364 (237,918) 23,206 Government subsidies / grants -- 1,690,974 -- 1,417,859 Income / (loss) before minority interest and income taxes (4,013,811) (5,744,065) (627,825) 2,037,801 Income taxes (907,176) -- (382,368) -- Minority interest 256,486 (1,525,486) 168,270 (1,058,870) Net income / (loss) $(4,664,501) $(7,269,551) $(841,923) $978,931 Earnings / (loss) per share - basic $(0.05) $(0.08) $(0.01) $0.01 Weighted average shares outstanding - basic 100,887,853 96,872,524 101,556,376 97,359,178 Earnings / (loss) per share - diluted $(0.05) $(0.06) $(0.01) $0.01 Weighted average shares outstanding - diluted 100,887,853 125,103,425 101,556,376 131,377,347 Benda Pharmaceutical, Inc., Balance Sheet (In thousands, except share and per share data) September 30 December 31 2008 2007 (Unaudited) Assets Current Assets Cash and cash equivalents $1,685,375 $1,266,240 Trade receivables, net 11,895,149 10,472,233 Other receivables
'/>"/>
SOURCE Benda Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Benda Pharmaceutical Files Amendment To Form S-1
2. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
3. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
4. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
5. ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
6. NanoBio to Give Four Scientific Presentations at Upcoming National Meeting of Pharmaceutical Scientists
7. Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
9. White Paper Details How DNA Sequencing Services Can Prevent Cleanroom Shutdowns at Medical Device and Pharmaceutical Manufacturers
10. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
11. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... Dec. 22, 2014 GenomeDx Biosciences today announced ... Cancer Classifier, a genomic test for prostate cancer, was ... men managed by radical prostatectomy without adjuvant therapy. Although ... relatively uncommon, using tumor genomics to identify these men ... is an important advance. The study has been ...
(Date:12/22/2014)... 22, 2014 ITRA Global, one of ... of commercial real estate, has further expanded its global ... Perth and Brisbane, Western Australia, reports Mylinda Vick, CCIM, ... ITRA Global / ACORPP (Australian Corporate Property and ... company providing property services to a wide range of ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that ... Aflatoxin M1 in raw commingled milk is the first ... The peer reviewed report of the validation by Technology ... and Fisheries Research (ILVO-T&V) has been published by the ... most toxic aflatoxin and a known carcinogen, can be ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... VILLAGE, Nev., Nov. 23 PDL BioPharma, Inc. (PDL) (Nasdaq: ... 27, 2009 as the ex-dividend date for its $200 million ... on November 2, 2009. The dividend will be paid on ... record date, December 1, 2009. NASDAQ has set the ...
... 23 /PRNewswire/ - Inimex Pharmaceuticals, Inc. announced today that it ... CEO. , Abrams brings more than 25 years of drug ... of the nuclear medicine imaging agent, Cardiolite, and worked from ... Manager, Biomedical Research Worldwide. In 1996, Abrams led the establishment ...
... countries have an opportunity to take the lead in ... Valencia (UV), working together with the IDICHUS Foundation, have ... Their conclusion is that Spain,s food and plant sectors ... Biotechnology as applied to food and plants has been ...
Cached Biology Technology:PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2Inimex Announces Appointment of New CEO 2Spanish biotechnology should focus on food and plant sectors to be more competitive 2
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
(Date:11/21/2014)... Nov. 20, 2014   Atmel® Corporation (NASDAQ: ... (MCU) and touch technology solutions, today launched the industry,s ... with the widest V cc range from 1.7V ... and faster I 2 C bus communication speeds, and ... memory making them ideal for consumer, industrial, computer, and ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... recently presented preliminary research findings that identify a specific ... diseases. Two research studies funded by grants ... the National Institutes of Health (NIH) examined the role ... Type 2 diabetes and other obesity-related cardiovascular diseases. The ...
... Scientists are reporting first use of a new method ... recycle, and reuse nanoparticles, some of which ounce for ... which offers a solution to a nagging problem, could ... cells, flexible electronic displays, and other products, the scientists ...
... Researchers have identified a gene that appears to increase ... common type of Alzheimer,s disease. The research will be presented ... Academy of Neurology,s 62nd Annual Meeting in Toronto, April 10 ... chromosome six. "Only recently have common variants in ...
Cached Biology News:EVMS researchers identify potential target for treatment of obesity-related diseases 2New gene associated with increased risk of Alzheimer's disease 2
Unique enzyme blend containing Taq and Pwo DNA Polymerase and another thermostable enzyme. The Expand 20 kbPLUS PCR System also includes an optimized reaction buffer, MgCl2 solution, and a human cont...
... polyacrylamide gel electrophoresis (2D-PAGE) with biological mass ... technology platform for proteomic analysis. 2D-PAGE gels ... limited only in the dynamic range and ... Quantitative image based analysis of separated proteins ...
... offers precision beveling of micropipette ... The unique abrasive plate drive ... greater control of the beveling ... very rapidly and produces consistent ...
... lightweight, high current power supply capable of producing ... is an excellent choice for PAGE, SDS-PAGE and ... ideal for all types of electroblotting applications.A dual ... end a run and wil automatically accrue elapsed ...
Biology Products: